Fig. 1: Survival curves according to the ADI-PEG20 with cisplatin in all cohorts. | British Journal of Cancer

Fig. 1: Survival curves according to the ADI-PEG20 with cisplatin in all cohorts.

From: Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

Fig. 1

a Progression-free survival curve; b Overall survival curve. Dose-Esc dose-escalation cohorts (combined for this analysis), MTD-B HCC-with-BTC or BTC-alone cohort, MTD C cutaneous melanoma cohort, MTD-H HCC cohort, MTD-O ovarian carcinoma cohort, MTD-U uveal melanoma cohort.

Back to article page